Formosa Pharmaceuticals, Inc.’s Post

Medcura, Inc. has closed a private placement with aggregate gross proceeds of $22.4 million. We will use these funds to accelerate the development of our lead surgical product, LifeGel™ Absorbable Hemostatic Gel, complete pre-clinical testing of the product, and file an Investigational Device Exemption for LifeGel with the U.S. FDA to support an investigational study focused on stopping bleeding in spinal surgery. Current hemostatic agents swell and can cause neurological issues, including paralysis, when used in confined spaces routinely addressed in spinal surgery.   Medcura’s Chief Executive Officer Jim Buck stated, “We remain highly encouraged by the continued momentum and pace of successes around our Life™ platform of innovative surgical hemostatic agents. Our new and existing investor partners understand, and are aligned with, the Company’s strategy to seismically transform the $2.8 billion worldwide biosurgery market for hemostatic agents. This funding support is timely and crucial to further advance our progress into a pivotal clinical trial and global commercialization of the platform’s lead product, LifeGel.”  #biotech #surgery #Medcura

Formosa Pharmaceuticals, Inc. Presents Top-Line Data of P-III (CPN-303) Study Evaluating APP13007 for Inflammation and Pain Post Cataract Surgery in Chinese Patients #formosapharmaceuticals #app13007 #inflammation #pain #clinicaltrial #cataractsurgery #chinesepatients

How placebo works 2... The pain relief effects of a placebo are related to the brain producing endorphins to suppress pain, I focused on the immune system mainly in my previous post. A placebo is actually hypnosis, it is works exactly by the same mechanism when it provides pain relief. While this is alright for a surgery, yes hypnotic anaesthesia is possible during a surgery, it is not advisable to suppress pain without handling it's root cause otherwise. As we already know, pain is a signal from our body that something is wrong, so one should not suppress pain without handling the root cause be it through placebo, hypnotherapy or pharmaceutical analgesics.

Patients with Hidradenitis Suppurativa (HS) are offered antibiotics and surgery, but these therapies do little to support the condition long-term. Currently, approved biologics only work for some patients, but with over 20 companies developing new treatments, hope is on the horizon. Gain analysis from clinical experts on the treatment options and how to meet patients’ needs by downloading our infographic: https://bit.ly/4dWjgs9 #HidradenitisSuppurativa #LivingwithHS #PatientJourney #HSResearch

Current treatment options for #pterygium, an #OcularDisease, include over-the-counter topical treatments and surgery — both with considerable drawbacks. That’s why there’s an urgent need for more effective, lasting alternatives.      While there are no FDA-approved drugs for pterygium, Cloudbreak is developing the first potential therapy for this condition, which is now in Phase 3 clinical trials. Learn more about our work: https://lnkd.in/e_UnxjTr 

A needle- and opioid-free sedative for patients undergoing cataract surgery progresses in its Phase 3 clinical trial: https://lnkd.in/gvmMFsui

Induction of beige fat for grafting is an emerging transplantation strategy. However, safety concerns associated with pharmaceutical interventions limit its wider application. Moreover, because beige fat is a special type of fat with strong metabolic functions, its effect on the metabolism of recipients after grafting has not been explored in the plastic surgery domain. Objectives The aim of this study was to explore whether cold-induced inguinal white adipose tissue (iWAT) transplantation has a higher retention rate and beneficial effects on recipient metabolism. 🔗Read the paper: https://lnkd.in/ge7EAZBK

A needle- and opioid-free sedative for patients undergoing cataract surgery progresses in its Phase 3 clinical trial: https://lnkd.in/gvmMFsui

The introduction of injectable glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic (Novo Nordisk, Plainsboro, NJ) and Wegovy (Novo Nordisk Inc.) has transformed weight loss in plastic surgery patients, often leading to excess skin and soft tissue amenable to body contouring procedures. Objectives The aim of this study was to examine the relationship between injectable GLP-1 receptor agonist use and the growing need for body contouring surgeries, focusing on trunk and extremity procedures. 🔗Read, cite, share the paper: https://lnkd.in/emUaWvPc